Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-02-10-Speech-1-086"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-02-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Authorisation of generic medicines at WTO level2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20030210.8.1-086"2
lpv:hasSubsequent	lp_eu:2003-02-10-Speech-1-0872
lpv:speaker	lp:Elly Plooij-van Gorsel2
lpv:spokenAs	member; Conference of Delegation Chairs (2002-02-07--2004-07-19)3 member; ELDR (1999-07-20--2004-07-19)3 unknown; Volkspartij voor Vrijheid en Democratie (1999-07-20--2004-07-19)3 chair; Delegation for relations with the People's Republic of China (2002-02-07--2004-07-19)3 member; Committee on Industry, External Trade, Research and Energy (2002-01-17--2004-07-19)3 substitute; ECON (2002-01-17--2004-07-19)3
lpv:translated text	"The arrangements made in Doha are crucial for allowing people in developing countries better access to medicines, particularly those for diseases associated with poverty. My group is of the opinion that Commissioner Lamy has taken some excellent initiatives with a view to making healthcare more easily accessible, including in the poorest countries and specifically in those countries that do not have their own production capacity. I would, however, like to put forward one criticism, although I agree with all the things that have been said here. Access to medicines is not only a question of money. There are two other issues that I would like to raise. Firstly the infrastructure in the countries concerned, and in this case I am talking about distribution and about which people in those countries get access to these medicines. Distribution means that there must be an infrastructure, something that is completely absent in many poor countries. What is even worse: this is not a priority for the regimes in the countries concerned. For example, a person taking AIDS medicines has to take them up to three times a day every day. This means that they have to stick rigidly to their treatment regime and that distribution channels are therefore needed to ensure that the patients concerned can always obtain their medicines. If this does not happen, the remedy will be worse than the disease, because people will become resistant to these diseases and that will ultimately work its way through to Western countries as well. Then new medicines will have to be developed. That is my first point. My second point is that regimes are often, in fact, corrupt. In such cases it turns out that the only medicines that are made available are the ones we have exported to these countries at low tariffs or the ones that can be produced there without patents, and even then they are only available to the better-off and not to the poorest population groups for whom we had intended them. What is more, they are sometimes re-exported or simply exported to Western countries."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph